4:29 AM
 | 
Jun 12, 2018
 |  BC Extra  |  Clinical News

Lilly, AZ stop Phase III Alzheimer's trials of BACE inhibitor

Eli Lilly and Co. (NYSE:LLY) and AstraZeneca plc (LSE:AZN; NYSE:AZN) discontinued a pair of Phase III trials evaluating once-daily oral lanabecestat (AZD3293, LY3314814) to treat Alzheimer's disease after an IDMC analysis concluded that both trials were unlikely to meet their primary endpoints. Lanabecestat is a beta-site APP-cleaving enzyme (BACE) inhibitor.

The partners stopped the Phase III AMARANTH trial in patients with early AD and the Phase III DAYBREAK-ALZ...

Read the full 316 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >